AIRLINK 71.69 Decreased By ▼ -2.41 (-3.25%)
BOP 5.00 No Change ▼ 0.00 (0%)
CNERGY 4.39 Increased By ▲ 0.05 (1.15%)
DFML 28.55 Decreased By ▼ -0.99 (-3.35%)
DGKC 82.40 Decreased By ▼ -1.15 (-1.38%)
FCCL 21.95 Decreased By ▼ -0.48 (-2.14%)
FFBL 34.15 Decreased By ▼ -0.75 (-2.15%)
FFL 10.08 Increased By ▲ 0.21 (2.13%)
GGL 10.12 Increased By ▲ 0.12 (1.2%)
HBL 113.00 Increased By ▲ 1.00 (0.89%)
HUBC 140.50 Increased By ▲ 2.81 (2.04%)
HUMNL 8.03 Increased By ▲ 1.05 (15.04%)
KEL 4.38 Decreased By ▼ -0.02 (-0.45%)
KOSM 4.50 Decreased By ▼ -0.09 (-1.96%)
MLCF 38.01 Decreased By ▼ -0.54 (-1.4%)
OGDC 134.69 Decreased By ▼ -1.91 (-1.4%)
PAEL 26.62 Increased By ▲ 1.48 (5.89%)
PIAA 25.40 Decreased By ▼ -1.11 (-4.19%)
PIBTL 6.55 Decreased By ▼ -0.10 (-1.5%)
PPL 121.95 Decreased By ▼ -3.45 (-2.75%)
PRL 27.73 Decreased By ▼ -0.48 (-1.7%)
PTC 13.80 Decreased By ▼ -0.50 (-3.5%)
SEARL 54.89 Increased By ▲ 0.29 (0.53%)
SNGP 69.70 Decreased By ▼ -1.50 (-2.11%)
SSGC 10.40 Decreased By ▼ -0.10 (-0.95%)
TELE 8.50 Decreased By ▼ -0.02 (-0.23%)
TPLP 10.95 Increased By ▲ 0.01 (0.09%)
TRG 60.90 Increased By ▲ 0.20 (0.33%)
UNITY 25.22 Decreased By ▼ -0.11 (-0.43%)
WTL 1.28 Increased By ▲ 0.02 (1.59%)
BR100 7,638 Decreased By -26.7 (-0.35%)
BR30 24,972 Decreased By -54 (-0.22%)
KSE100 72,761 Decreased By -3 (-0%)
KSE30 23,625 Decreased By -150.3 (-0.63%)

LONDON: British pharmaceutical giant AstraZeneca said Thursday that a third, or "booster", dose of its Covid-19 vaccine Vaxzevria "significantly" lifted antibody levels against the Omicron strain in a laboratory study.

"Vaxzevria significantly boosted levels of antibodies against the Omicron SARS-CoV-2 variant (B.1.1.529) following a third dose booster," the company said in a statement citing the study.

"The third dose booster vaccination neutralised the Omicron variant to levels that were broadly similar to those observed... after the second dose against the Delta variant," it said.

Levels of neutralising antibodies were also higher with the booster jab than with individuals who had previously been infected and recovered naturally from Covid-19.

The study was conducted by investigators from the University of Oxford, which is the academic institution which helped AstraZeneca develop the vaccine last year.

Moderna says full booster dose improves Omicron protection

The study analysed blood samples taken from individuals infected with Covid-19; those vaccinated with two doses plus a booster; and those who had reported previous Covid infection.

"It is very encouraging to see that current vaccines have the potential to protect against Omicron following a third dose booster," said University of Oxford professor John Bell, one of the study investigators.

"These results support the use of third dose boosters as part of national vaccine strategies, especially to limit the spread of variants of concern, including Omicron."

On Wednesday, the World Health Organization had warned that rich countries cannot use boosters to escape the Covid crisis, as they divert valuable jabs away from poorer nations -- and encourage the virus to spread and mutate.

J&J, Sinopharm, Sputnik V COVID-19 shots less effective against Omicron: study

The threat of the highly transmissible Omicron variant is looming large over the end-of-year holidays, pushing many governments to roll out new restrictions and urge citizens to get vaccinated.

The latest data suggest Omicron does not cause more severe illness than previous variants, including Delta, but as soaring infection numbers threaten to overwhelm health systems, scientists warn it could still cause more deaths.

Comments

Comments are closed.